Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
乔垣结衣
5个月前
148
50
已完结
1. 系统已在2025-05-13 11:44:47对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
出版社: Elsevier BV
作者: Shukui Qin; Qiu Li; Shanzhi Gu; Xiaoming Chen; Lizhu Lin; Zishu Wang; Aibing Xu; Xi Chen; Cuncai Zhou; Zhenggang Ren; Lin Yang; Li Xu; Yuxian Bai; Lei Chen; Jun Li; Hongming Pan; Bangwei Cao; Weijia Fang; Wei Wu; Ge Wang; Ying Cheng; Zhuang Yu; Xu Zhu; Da Jiang; Yinying Lu; Huaming Wang; Jianming Xu; Li Bai; Yunpeng Liu; Hailan Lin; Changping Wu; Yang Zhang; Ping Yan; Chunlei Jin; Jianjun Zou
